Investment Thesis — Neurocrine Biosciences, Inc.
The market underestimates the durability and pricing power of Neurocrine's core franchise, mispricing its ability to sustain high margins and cash flow even as growth moderates. Investors are overly focused on near-term pipeline risk and ignore the embedded optionality from a structurally advantaged CNS portfolio.
Catalysts
- Positive data or FDA approval for pipeline CNS indications
- Label expansion for core product driving new patient populations
- Strategic M&A or partnership that diversifies revenue base
Risk Factors
- Pipeline clinical trial failures or regulatory setbacks
- Payer pushback or pricing pressure on lead therapy
- Emergence of new CNS competitors or disruptive therapies
Key Debates
NBIX P/E re-rates to 25x by Q4 2024
Short float drops below 3% by Q3 2024
Gross margin sustains above 97% through FY24